Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes

Ding,Kai; Fu,Rong; Liu,Hui; Nachnani,Deepak  Anil; Shao,Zong‑Hong

doi:10.3892/ol.2016.4259

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes

Authors:
- Kai Ding
- Rong Fu
- Hui Liu
- Deepak Anil Nachnani
- Zong‑Hong Shao
View Affiliations

Affiliations: Department of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, P.R. China
Published online on: February 23, 2016 https://doi.org/10.3892/ol.2016.4259
Pages: 2347-2352
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thrombocytopenia is a common, often fatal complication experienced by patients with myelodysplastic syndromes (MDS). 5-aza-2'‑deoxycytidine (decitabine) has been used to treat MDS patients with thrombocytopenia with a response rate of 45‑50%. However, the mechanism of its effects on megakaryocytes remains unclear. In the present study, the effect of decitabine on megakaryocyte maturation was investigated. A total of 20 MDS patients diagnosed with thrombocytopenia were enrolled, including 16 refractory anemia with excess blasts (RAEB)‑1 patients and 4 RAEB‑2 patients], in addition to 20 leukemia patients that had achieved complete remission and 20 healthy donors. Overall, 65% of MDS patients exhibited a response to decitabine, with an increase in platelet count identified in 80% of patients. In the MDS group, the mean platelet count was significantly increased following one cycle of decitabine chemotherapy (36.85±24.54 vs. 84.90±61; P=0.001); however, no significant difference in megakaryocyte number was identified prior to and following treatment. Additionally, bone marrow mononuclear cells of the MDS patients were cultured in vitro with various concentrations of decitabine (0.0, 2.0, 2.5, 3.0 µM), and cluster of differentiation (CD)41 levels were examined via flow cytometry. The MDS and normal control groups exhibited the highest levels of CD41 expression following treatment with 2.0 µM decitabine (mean fluorescence intensity, 294.07±47.34 and 258.95±28.05, respectively). In conclusion, these results indicate that the DNA‑hypomethylating agent, decitabine, may induce the differentiation and maturation of myelodysplastic megakaryocytes in MDS patients, even at low concentrations. Thus, the repeated administration of decitabine at lower doses in MDS patients may be useful in clinical practice, and may lead to the development of alternative treatments for other diseases of abnormal megakaryocyte differentiation, such as idiopathic thrombocytopenic purpura, however, future studies are required to investigate this.

View Figures

View References

1	Steensma DP and Tefferi A: The myelodysplastic syndrome(s): A perspective and review highlighting current controversies. Leuk Res. 27:95–120. 2003. View Article : Google Scholar : PubMed/NCBI
2	Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R and Leveque J: The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 109:1705–1714. 2007. View Article : Google Scholar : PubMed/NCBI
3	Webb JJ and Anderson KC: Risks, costs and alternatives to platelet transfusion. Leuk Lymphoma. 34:71–84. 1999. View Article : Google Scholar : PubMed/NCBI
4	List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R and Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 352:549–557. 2005. View Article : Google Scholar : PubMed/NCBI
5	Richel DJ, Colly LP, Kluin-Nelemans JC and Willemze R: The antileukemic activity of 5-aza-2-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer. 64:144–148. 1991. View Article : Google Scholar : PubMed/NCBI
6	Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A: Cytogenetic responses in high-risk myelodysplastic syndromes following low-dose treatment with the DNA methylation inhibitor 5-aza-2-deoxycytidine. Br J Haematol. 114:349–357. 2001. View Article : Google Scholar : PubMed/NCBI
7	de Vos D and van Overveld W: Decitabine: A historical review of the development of an epigenetic drug. Ann Hematol. 84(Suppl 1): S3–S8. 2005. View Article : Google Scholar
8	Hennessy BT, Garcia-Manero G, Kantarjian HM and Giles FJ: DNA methylation in haematological malignancies: The role of decitabine. Expert Opin Investig Drugs. 12:1985–1993. 2003. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Yi Z, Wang S and Li Z: The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost. 106:337–343. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wijermans P, Krulder JW, Huygens PC and Neve P: Continous infusion of low dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndromes. Leukemia. 11:1–5. 1997. View Article : Google Scholar : PubMed/NCBI
11	Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A: Low dose 5-aza-2′-deoxycytidine, a DNA-hypomethylating agent for the treatment of high-risk myelodysplastic syndromes: A multicenter phase II study in elderly patients. J Clin Oncol. 18:956–962. 2000.PubMed/NCBI
12	Van den Bosch J, Lübbert M, Verhoef G and Wijermans PW: The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 28:785–790. 2004. View Article : Google Scholar : PubMed/NCBI
13	Peng HY and Liao HF: Staurosporine induces megakaryocytic differentiation through the upregulation of JAK/Stat3 signaling pathway. Ann Hematol. 90:1017–1029. 2011. View Article : Google Scholar : PubMed/NCBI
14	Brunning R, Orazi A, Germing U, et al: Myelodysplastic syndromes. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue. Swerdlow S, Campo E, Harris NL, et al: (4th). IARC Press. (Lyon, France). 88–103. 2008.
15	Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Wiliman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, et al: International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 21:4642–4649. 2003. View Article : Google Scholar : PubMed/NCBI
16	Greenberg PL, Attar E, Bennett JM, et al: National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes. J Natl Compr Canc Netw. 9:30–56. 2011.PubMed/NCBI
17	Gajendra S, Jha B, Goel S, Sahni T, Sharma R, Shariq M, Jaiswal S and Sachdev R: Leishman and Giemsa stain: A new reliable staining technique for blood/bone marrow smears. Int J Lab Hematol. Jul 30–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
18	Mori H, Niikura H, Terada H and Fujita K: Morphological analysis of the megakaryocytes in myelodysplastic syndrome. Rinsho Byori. 38:1347–1352. 1990.(In Japanese). PubMed/NCBI
19	Bluteau D, Lordier L, Di Stefano A, Chang Y, Raslova H, Debili N and Vainchenker W: Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost. 7(Suppl 1): 227–234. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gao X, Wu J, Zou W and Dai Y: Two ellagic acids isolated from roots of sanguisorba officinalis L. Promote hematopoietic progenitor cell proliferation and megakaryocyte differentiation. Molecules. 19:5448–5458. 2014. View Article : Google Scholar : PubMed/NCBI
21	Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A and MacBeth KJ: Lenalidomide as a disease-modifying agent in patients with del (5q) myelodysplastic syndromes: Linking mechanism of action to clinical outcomes. Ann Hematol. 93:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
22	Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G and Horny HP: Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS) and their distinction from low risk MDS. Leuk Res. 36:1–5. 2012.PubMed/NCBI
23	Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belangerc K and Ayoub J: Pilot phase I–II study on 5-aza-2-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 8:358–368. 1997. View Article : Google Scholar : PubMed/NCBI
24	Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W and DeSimone J: 5-Aza-2-deoxycytidine and foetal haemoglobin induction in sickle cell anaemia. Blood. 96:2379–2384. 2000.PubMed/NCBI